Free tool
FAERS Monitor: Apadaz
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 208653 or its brand name (Apadaz, Acetaminophen, Benzhydrocodone Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
21
Serious
15
71% of reports
Hospitalization
7
Death reported
1
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use5
- product dose omission issue5
- urinary tract infection4
- fluid retention3
- kidney infection3
- localised infection3
- peripheral swelling3
- rash3
- skin discomfort3
- condition aggravated2
- decreased appetite2
- diarrhoea2
- drug ineffective2
- infection2
- injection site pain2
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2020 | 1 |
| 2021 | 2 |
| 2023 | 4 |
| 2024 | 5 |
| 2025 | 5 |
| 2026 | 4 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,138 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| skin discomfortSignal | 3 | 1115.2 | 390.9 | 2,316 |
| kidney infectionSignal | 3 | 153.2 | 53.7 | 314 |
| localised infectionSignal | 3 | 124.3 | 43.6 | 254 |
| fluid retentionSignal | 3 | 59.1 | 20.7 | 118 |
| urinary tract infectionSignal | 4 | 23.5 | 9.7 | 66 |
| peripheral swellingSignal | 3 | 19.5 | 6.8 | 36 |
| product dose omission issueSignal | 5 | 17.0 | 7.9 | 61 |
| infection | 2 | 13.8 | 3.7 | 13 |
| decreased appetite | 2 | 8.6 | 2.3 | 7 |
| rashSignal | 3 | 6.9 | 2.4 | 10 |
| condition aggravated | 2 | 6.6 | 1.8 | 5 |
| injection site pain | 2 | 6.5 | 1.7 | 5 |
| off label useSignal | 5 | 5.7 | 2.7 | 16 |
| diarrhoea | 2 | 3.1 | 0.8 | 1 |
| drug ineffective | 2 | 1.5 | 0.4 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.